BioRestorative Therapies, Inc. Stock

Equities

BRTX

US0906556065

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:05:19 2024-04-23 pm EDT 5-day change 1st Jan Change
1.395 USD +1.09% Intraday chart for BioRestorative Therapies, Inc. +6.87% -19.54%
Sales 2024 * 60K Sales 2025 * 60K Capitalization 9.34M
Net income 2024 * -17M Net income 2025 * -20M EV / Sales 2024 * 156 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 156 x
P/E ratio 2024 *
-0.65 x
P/E ratio 2025 *
-0.66 x
Employees 11
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.2%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.09%
1 week+6.87%
Current month+1.45%
3 months-16.91%
6 months-25.93%
Current year-19.54%
More quotes
1 week
1.23
Extreme 1.23
1.45
1 month
1.21
Extreme 1.21
1.65
Current year
1.20
Extreme 1.2
3.67
1 year
1.20
Extreme 1.2
7.13
3 years
1.20
Extreme 1.2
54.00
5 years
0.40
Extreme 0.4
2 950.40
10 years
0.40
Extreme 0.4
49 000.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 18-09-30
Director of Finance/CFO - 21-11-03
Compliance Officer 55 15-08-31
Members of the board TitleAgeSince
Director/Board Member 51 21-10-28
Director/Board Member 59 21-10-28
Chief Tech/Sci/R&D Officer 49 11-04-12
More insiders
Date Price Change Volume
24-04-23 1.4 +1.45% 31 967
24-04-22 1.38 +0.73% 60,282
24-04-19 1.37 -4.86% 168,414
24-04-18 1.44 +3.60% 246,370
24-04-17 1.39 +6.11% 668,222

Delayed Quote Nasdaq, April 23, 2024 at 12:37 pm EDT

More quotes
BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The Company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.38 USD
Average target price
10.5 USD
Spread / Average Target
+660.87%
Consensus